A Closer Look at Allergan’s US General Medicines Segment
US General Medicines segment
Allergan’s (AGN) US General medicines segment includes central nervous system products, gastroenterology products, anti-infective products, women’s health products, and established brands.
Interested in AGN? Don't miss the next report.
Receive e-mail alerts for new research on AGN
The segment reported a 1.5% fall in revenues to $1.43 billion during 2Q17, compared to $1.45 billion in 2Q16, driven by lower sales of Namenda XR, Asacol, and Minastrin 24. This fall was substantially offset by increased sales of Linzess, Lo Loestrin, Namzaric, Viberzi, and Vraylar in 2Q17.
Specific product revenues
The anti-infectives franchise reported a 7.4% YoY (year-over-year) growth in revenues to $67.8 million in 2Q17, driven by increased sales of Avycaz and Dalvance, partially offset by lower sales of Teflaro.
The central nervous system franchise includes Alzheimer’s products and reported 9.2% growth in revenues to $346.6 million in 2Q17, driven by increased sales of Namzaric, Saphris, Viibryd, and Vraylar. This growth was substantially offset by lower sales of Namenda XR.
Diversified brands reported a 1% YoY fall in revenues to $305.5 million in 2Q17. The gastroenterology franchise reported a 7.1% YoY fall in revenues to $410.8 million in 2Q17, driven by lower sales of Asacol-Delzicol, but the strong sales of Linzess, Viberzi, and Zenpap partially offset this decline.
The women’s health franchise reported a 16.2% YoY fall in revenues to $248.0 million in 2Q17, driven by lower sales of Estrace Cream and Minastrin 24. This fall was partially offset by the strong performance of Lo Loestrin and Taytulla.